Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 8, 1999

View Archived Issues

New platinum analogue assessed in advanced gastric cancer patients

CCK-B antagonist CI-988 not effective in panic disorder

Calphostin C tested as photodynamic therapy in bladder cancer cell lines

Company Profile: Juvantia

Projected enrollment exceeded in Miravant's phase III AMD trials

Chiron and Scios complete FGF agreement

Select Therapeutics extends agreement with Institut Curie for cancer vaccine

DepoMed forms joint venture with Elan for gastric retention delivery technologies

Preparation and use of inhibitors of sodium-dependent Cl-/HCO3- exchange

CRCT discloses new cyclopropylindoles for ADEPT and/or GDEPT of cancer

Analgesic NOS inhibitors described in patent literature by Otsuka

New cephalosporins from Toyama active against resistant strains

Inhibitor of p38 MAP kinase significantly attenuates brain damage in stroke models

Japanese investigators describe work in the area of cysteine protease inhibitors at recent meeting

AstraZeneca drops TCAR MAb following phase II studies

Biogen reports phase II data for antipsoriatic agent and advances product to phase III

FDA advisory panel will review MS indication for Novantrone in early 2000

Hughes Institute team describes research into platinum complexes

Novartis reports setbacks and advances in the development of new chelating agents

Early indications of therapeutic benefit with Coagulin-B

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...